The ghrelin receptor's constitutive activity, oligomerization, and tissue-specific signaling make it a complex but promising drug target for obesity — requiring sophisticated pharmacological approaches beyond simple agonism or antagonism.
Key findingGHS-R1a's constitutive activity, homo/hetero-oligomerization, and biased signaling create complex pharmacology requiring inverse agonists, biased liga
What the researchers found
GHS-R1a's constitutive activity, homo/hetero-oligomerization, and biased signaling create complex pharmacology requiring inverse agonists, biased ligands, or allosteric modulators rather than simple agonists/antagonists for effective obesity drug development.
Why it matters
Relevant for ghrp, weight-loss, receptor-signaling.
How the study worked
review study on ghrp, weight-loss.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2006.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Growth hormone secretagogue (ghrelin-) receptors--a complex drug target for the regulation of body weight.
CNS & neurological disorders drug targets, 5(3), 335-43
Citation
Nogueiras, R; Perez-Tilve, D; Wortley, K E; Tschöp, M. (2006). Growth hormone secretagogue (ghrelin-) receptors--a complex drug target for the regulation of body weight.. CNS & neurological disorders drug targets, 5(3), 335-43.